1.
Gordon K, Papp K, Gooderham M, Morita A, Foley P, Tha?i D, Kundu S, Kisa R, Wei L, Banergee S. BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients. J of Skin [Internet]. 2020Sep.2 [cited 2022Jun.30];4(5):s28. Available from: https://www.jofskin.org/index.php/skin/article/view/977